Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Biotechnology

Healthcare
$3.95 +2.36%

+$0.09 today

Market cap
$86.45M
Beta
4.47
P/E (TTM)
-1.2
EPS (TTM)
-$3.20
52W Low $3.35High $17.94

Volume 1.32M

Average 0.18M

AARD EBITDA Margin

EBITDA as a percentage of revenue.

No reported EBITDA Margin figures are available to summarize.

EBITDA Margin history

Percent of revenue · from the income statement

No EBITDA Margin data reported for this period type.

EBITDA Margin vs competitors

How AARD compares with its peers on the latest reported figures

AARD Competitors Peer median
EBITDA Margin for AARD and competitors
Company Period LTM level YoY 3-year change
ASMBAssembly Biosciences, Inc.LTM Mar 2026-8.8% +113.4 pp—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-67.3% +67.9 pp+30.0 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-257.0% +77.3 pp+319.4 pp
PYXSPyxis Oncology, Inc.LTM Mar 2026-547.9% ——
CRBUCaribou Biosciences, Inc.LTM Mar 2026-999.5% +475.3 pp-608.7 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-33540.9% ——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-142957.6% -159600.9 pp-131573.1 pp
AARDAardvark Therapeutics, Inc. Common StockFY2025— ——
ZURAZura Bio LimitedFY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
Peer median (excluding AARD) -547.9%+77.3 pp-289.3 pp

Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development7.17M4.48M17.36M48.94M
Selling, General & Admin2.7M2.17M5.31M13.79M
Operating Expenses11.36M7.42M22.79M62.73M
Depreciation & Amortization110K97K16K36K
EBITDA(10.76M)(6.56M)(22.65M)(57.56M)
EBITDA Margin————
Operating Income(11.36M)(7.42M)(22.79M)(62.73M)
Operating Margin————
Interest Income120K1.42M2.41M5.14M
Interest Expense0000
Other Income / Expenses(2.2M)207K2.2M5.13M
Income Before Tax(13.56M)(7.21M)(20.59M)(57.59M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(13.56M)(7.21M)(20.59M)(57.59M)
Net Margin————
EPS (Basic)(0.63)(0.34)(0.95)(2.64)
EPS (Diluted)(0.63)(0.34)(0.95)(2.64)
Weighted Avg Shares21.38M21.38M21.7M21.82M
Weighted Avg Shares (Diluted)21.38M21.38M21.7M21.82M

Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Intrinsic Alpha fair value

Locked

Current Price

$3.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.